Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1172 ARTÍCULOS , VIENDO DEL 826 AL 840

Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease

Straten G, Saur R, Laske C, Gasser T, Annas P, Basun H, Leyhe T.

Curr Alzheimer Res. 2011 Dec;8(8):853-9. doi: 10.2174/156720511798192754.

No association between hypertension and risk for Alzheimer's disease: a meta-analysis of longitudinal studies

Guan JW, Huang CQ, Li YH, Wan CM, You C, Wang ZR, Liu YY, Liu QX.

J Alzheimers Dis. 2011;27(4):799-807. doi: 10.3233/JAD-2011-111160.

[Alzheimer's disease, amyloid peptide and synaptic dysfunction]

Hémar A, Mulle C.

Med Sci (Paris). 2011 Aug-Sep;27(8-9):733-6. doi: 10.1051/medsci/2011278015. Epub 2011 Aug 31.

Neuropsychiatric symptoms in Alzheimer's disease

Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS.

Alzheimers Dement. 2011 Sep;7(5):532-9. doi: 10.1016/j.jalz.2011.05.2410.

Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study

Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, Bush AI.

J Alzheimers Dis. 2011;27(4):909-22. doi: 10.3233/JAD-2011-110752.

Loss of activated CaMKII at the synapse underlies Alzheimer's disease memory loss

Ly PT, Song W.

J Neurochem. 2011 Nov;119(4):673-5. doi: 10.1111/j.1471-4159.2011.07473.x.

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease

Ferreira ST, Klein WL.

Neurobiol Learn Mem. 2011 Nov;96(4):529-43. doi: 10.1016/j.nlm.2011.08.003. Epub 2011 Sep 6.

Central insulin and insulin-like growth factor-1 signaling: implications for diabetes associated dementia

Zemva J, Schubert M.

Curr Diabetes Rev. 2011 Sep;7(5):356-66. doi: 10.2174/157339911797415594.

Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease

Popp J, Arlt S.

Curr Opin Psychiatry. 2011 Nov;24(6):556-61. doi: 10.1097/YCO.0b013e32834b7b96.

Harm avoidance and risk of Alzheimer's disease

Wilson RS, Boyle PA, Buchman AS, Yu L, Arnold SE, Bennett DA.

Psychosom Med. 2011 Oct;73(8):690-6. doi: 10.1097/PSY.0b013e3182302ale. Epub 2011 Sep 23.

A comprehensive strategy for dementia from primary prevention to end-stage management

Arai H.

Psychogeriatrics. 2011 Sep;11(3):131-4. doi: 10.1111/j.1479-8301.2011.00379.x.

Presenile dementia diagnosed as posterior cortical atrophy

Tsunoda A, Iritani S, Ozaki N.

Psychogeriatrics. 2011 Sep;11(3):171-6. doi: 10.1111/j.1479-8301.2011.00366.x. Epub 2011 Jun 15.

Screening for dementia: an opportunity for debate

Ballard C, Corbett A.

Expert Rev Neurother. 2011 Oct;11(10):1347-9. doi: 10.1586/ern.11.121.

TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype

Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S, Yusuf I, Amin H, DuPlessis D, Troakes C, Al-Sarraj S, Sloan C, Esiri MM, Prasher VP, Allsop D, Neary D, Pickering-Brown SM, Snowden JS, Mann DM.

Acta Neuropathol. 2011 Dec;122(6):703-13. doi: 10.1007/s00401-011-0879-y. Epub 2011 Oct 4.

Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study

Arbus C, Gardette V, Cantet CE, Andrieu S, Nourhashémi F, Schmitt L, Vellas B; REAL.FR Group.

J Nutr Health Aging. 2011 Aug;15(8):609-17. doi: 10.1007/s12603-011-0061-1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias